LCN2 and breast cancer: Mice with breast cancer that received the AAV‐mDNase I vector had reduced urine levels of the biomarker NGAL compared to mice that received the AAV‐null control vector, confirming that the AAV‐mDNase I approach can suppress kidney dysfunction in a similar way as exogenously administered DNase I.7Three mice in the AAV‐null control group had to be terminated 2 weeks before the experimental endpoint due to early development of large primary tumors.